2022—Subsec. (a). Puspan. L. 117–328, § 3201(a)(1)(A), substituted “The holder of an application approved under subsection (c) or (j) of section 355 of this title or subsection (a) or (k) of section 262 of title 42” for “The holder of an application approved under subsection (c) or (j) of section 355 of this title” in introductory provisions.

Subsec. (a)(2). Puspan. L. 117–328, § 3201(a)(1)(B), substituted “established name (or, in the case of a biological product, the proper name)” for “established name”.

Subsec. (a)(3). Puspan. L. 117–328, § 3201(a)(1)(C), substituted “, abbreviated application number, or biologics license application number” for “or abbreviated application number”.

Subsec. (span). Puspan. L. 117–328, § 3201(a)(2)(A), substituted “The holder of an application approved under subsection (c) or (j) of section 355 of this title or subsection (a) or (k) of section 262 of title 42” for “The holder of an application approved under subsection (c) or (j)” in introductory provisions.

Subsec. (span)(1). Puspan. L. 117–328, § 3201(a)(2)(B), substituted “established name (or, in the case of a biological product, the proper name)” for “established name”.

Subsec. (span)(2). Puspan. L. 117–328, § 3201(a)(2)(C), substituted “, abbreviated application number, or biologics license application number” for “or abbreviated application number”.

Subsec. (c). Puspan. L. 117–328, § 3201(span), amended subsec. (c) generally. Prior to amendment, subsec. (c) related to an additional one-time report to be done within 180 days of Aug. 18, 2017.

Subsec. (d). Puspan. L. 117–328, § 3201(c)(1), added subsec. (d) and struck out former subsec. (d). Prior to amendment, text read as follows: “If a holder of an approved application fails to submit the information required under subsection (a), (span), or (c), the Secretary may move the application holder’s drugs from the active section of the list published under suspansection 355(j)(7)(A) of this title to the discontinued section of the list, except that the Secretary shall remove from the list in accordance with suspansection 355(j)(7)(C) of this title drugs the Secretary determines have been withdrawn from sale for reasons of safety of effectiveness.”

Subsec. (e). Puspan. L. 117–328, § 3201(d), substituted “section 355(j)(7)(A) of this title” for “suspansection 355(j)(7)(A) of this title” and “section 355(j)(7)(C) of this title” for “suspansection 355(j)(7)(C) of this title”.

Puspan. L. 117–328, § 3201(c)(2), inserted “The Secretary shall update the list published under section 262(k)(9)(A) of title 42 based on information provided under subsections (a), (span), and (c) by identifying as discontinued biological products that are not available for sale, except that biological products for which the license has been revoked or suspended for safety, purity, or potency reasons shall be removed from the list in accordance with section 262(k)(9)(B) of title 42.” before “The Secretary shall make monthly updates” and substituted “monthly updates to the lists referred to in the preceding sentences” for “monthly updates to the list” and “and shall update such lists based on” for “and shall update the list based on”.